The MDMA-assisted therapy organization, MAPS, has raised $10mn of the $30mn needed for Phase 3 trials for their treatment of PTSD. With investors committing funds, including a $5mn pledge from the Steven and Alexandra Cohen Foundation, MAPS is using a challenge grant to incentivize additional donations and fundraising towards the remaining $20mn.